Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review
J Am Acad Dermatol. 2024 Dec;91(6):1265-1267.
doi: 10.1016/j.jaad.2024.07.1515.
Epub 2024 Aug 23.
1 Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
2 Dermatology Research Institute, Calgary, Alberta, Canada.
3 Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
4 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
5 Skin Health & Wellness Centre, Calgary, Alberta, Canada.
6 Dermatology Research Institute, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Probity Medical Research, Waterloo, Ontario, Canada.
7 Division of Dermatology, McMaster University, Hamilton, Ontario, Canada; Dermatrials Research Inc. & Venderm Consulting, Hamilton, Ontario, Canada.
8 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Probity Medical Research, Waterloo, Ontario, Canada; Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
9 Dermatology Research Institute, Calgary, Alberta, Canada; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada. Electronic address: vimal@dermatologyresearch.ca.